Chronic gouty arthritis and kidney damage: a clinical example
- Authors: Poliakova V.V.1, Kunitskaya N.A.1
-
Affiliations:
- I.I. Mechnikov North-West State Medical University, Ministry of Health of Russia
- Issue: Vol 34, No 7 (2023)
- Pages: 54-56
- Section: From Practice
- URL: https://journals.eco-vector.com/0236-3054/article/view/568035
- DOI: https://doi.org/10.29296/25877305-2023-07-11
- ID: 568035
Cite item
Abstract
Gout is a pathological condition characterized by hyperproduction of uric acid due to increased synthesis of endogenous purines or impaired excretion of uric acid by the kidneys. Despite the popularity of the main classical clinical manifestations of gout, such as tofuses, increased uric acid levels and arthritis, its diagnosis still causes great difficulties. At the same time, gout is closely associated with impaired kidney function, which makes diagnosis difficult. In this article, using a clinical example, we consider typical cases that arise during the diagnosis of this pathology.
Keywords
Full Text
About the authors
V. V. Poliakova
I.I. Mechnikov North-West State Medical University, Ministry of Health of Russia
Author for correspondence.
Email: scvssd@yandex.ru
Candidate of Medical Sciences, Associate Professor
Russian Federation, Saint PetersburgN. A. Kunitskaya
I.I. Mechnikov North-West State Medical University, Ministry of Health of Russia
Email: scvssd@yandex.ru
Doctor of Medical Sciences, Professor
Russian Federation, Saint PetersburgReferences
- Cheng Shi, Ziting Zhou, Xiaowei et al. Recent advances in gout drugs. Eur J Med Chem. 2023; 245 (Pt 1): 114890. doi: 10.1016/j.ejmech.2022.114890
- Qaseem A., McLean R.M., Starkey M. et al. Diagnosis of acute gout: a clinical practice guideline from the American College of physicians. Ann Intern Med. 2017; 166 (1): 52–7. doi: 10.7326/M16-0569
- Richette P., Doherty M., Pascual E. et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017; 76 (1): 29–42. doi: 10.1136/annrheumdis-2016-20970
- Chenjing Wang, Qing Yu, Xin Jiang et al. A Drug–Drug Interaction Study of a Novel Selective Urate Reabsorption Inhibitor, SHR4640, and Xanthine Oxidase Inhibitor, Febuxostat, in Patients With Primary Hyperuricemia. J Clin Pharmacol. 2023; 63 (2): 239–49. doi: 10.1002/jcph.2159
- Mitsuboshi S., Kotake K. Association between use of febuxostat and muscle injury: A disproportionality analysis and meta-analysis of randomized controlled trials. Br J Clin Pharmacol. 2023; 89 (3): 956–66. doi: 10.1111/bcp.15655
- Te Kampe R., Boonen A., Jansen T. et al. Development of a patient decision aid for the initiation of urate-lowering therapy in gout patients. RMD Open. 2022; 8 (1): e001979. doi: 10.1136/rmdopen-2021-001979